

# Lorena Landuzzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2336920/publications.pdf>

Version: 2024-02-01

90  
papers

3,594  
citations

159358

30  
h-index

143772

57  
g-index

90  
all docs

90  
docs citations

90  
times ranked

4244  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.4	326
2	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	4.2	291
3	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	4.2	218
4	NVP-BE2235 as a New Therapeutic Option for Sarcomas. <i>Clinical Cancer Research</i> , 2010, 16, 530-540.	3.2	142
5	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 1322-1330.	3.2	126
6	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002, 101, 11-16.	2.3	96
7	Molecular and cellular biology of rhabdomyosarcoma. <i>Future Oncology</i> , 2009, 5, 1449-1475.	1.1	91
8	Inhibition of tumor growth and enhancement of metastasis after transfection of the $\beta$ -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	2.3	89
9	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- $\beta$ and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.4	88
10	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.4	87
11	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.4	83
12	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	3.3	83
13	Virus-like particle display of HER2 induces potent anti-cancer responses. <i>Oncolmmunology</i> , 2018, 7, e1408749.	2.1	82
14	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.4	78
15	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 $^{-/-}$ ;Il2rg $^{-/-}$ Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	1.1	78
16	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	2.3	75
17	The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit. <i>American Journal of Pathology</i> , 2000, 157, 2123-2131.	1.9	73
18	c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. <i>Journal of Clinical Oncology</i> , 2003, 21, 1952-1960.	0.8	71

#	ARTICLE	IF	CITATIONS
19	CD99 Acts as an Oncosuppressor in Osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006, 17, 1910-1921.	0.9	60
20	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937-941.		58
21	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. <i>Cancer Research</i> , 2003, 63, 2728-32.	0.4	53
22	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. <i>Scientific Reports</i> , 2019, 9, 12174.	1.6	52
23	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.4	47
24	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. <i>Gene</i> , 2001, 274, 139-149.	1.0	46
25	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1205-1216.	1.9	43
26	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. <i>PLoS ONE</i> , 2013, 8, e83832.	1.1	43
27	Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. <i>British Journal of Cancer</i> , 1995, 72, 1224-1229.	2.9	42
28	Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. <i>Clinical and Experimental Metastasis</i> , 1990, 8, 215-224.	1.7	39
29	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. <i>Current Drug Targets</i> , 2011, 12, 1957-1973.	1.0	39
30	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. <i>PLoS Pathogens</i> , 2013, 9, e1003155.	2.1	36
31	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1881-1892.	1.9	33
32	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). <i>International Journal of Cancer</i> , 2010, 126, 41-52.	2.3	31
33	Preclinical evaluation of KIT/PDGFR $\alpha$ and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 173.	3.5	31
34	The Immune Response Elicited by Mammary Adenocarcinoma Cells Transduced with Interferon- $\gamma$ and Cytosine Deaminase Genes Cures Lung Metastases by Parental Cells. <i>Human Gene Therapy</i> , 1998, 9, 217-224.	1.4	30
35	HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 314-323.	1.2	29
36	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <i>International Journal of Cancer</i> , 2003, 105, 384-389.	2.3	28

#	ARTICLE	IF	CITATIONS
37	Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. <i>International Journal of Cancer</i> , 1991, 48, 270-276.	2.3	27
38	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	2.2	27
39	High metastatic efficiency of human sarcoma cells in Rag2 $\beta$ c double knockout mice provides a powerful test system for antimetastatic targeted therapy. <i>European Journal of Cancer</i> , 2010, 46, 659-668.	1.3	26
40	Transduction of Genes Coding for a Histocompatibility (MHC) Antigen and for Its Physiological Inducer Interferon- $\beta$ in the Same Cell: Efficient MHC Expression and Inhibition of Tumor and Metastasis Growth. <i>Human Gene Therapy</i> , 1995, 6, 743-752.	1.4	23
41	Murine model for skeletal metastases of Ewing's sarcoma. <i>Journal of Orthopaedic Research</i> , 2000, 18, 959-966.	1.2	22
42	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 754-761.	1.9	20
43	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014, 15, S1.	1.2	20
44	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.4	19
45	Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. <i>Cells</i> , 2021, 10, 416.	1.8	19
46	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	0.8	19
47	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1993, 67, 674-679.	2.9	18
48	Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. , 1997, 71, 732-736.		17
49	Apc10.1: An ApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	2.3	17
50	Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. <i>Molecular Imaging and Biology</i> , 2010, 12, 616-625.	1.3	17
51	IFN- $\beta$ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	1.7	17
52	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. <i>Analytical Cellular Pathology</i> , 2011, 34, 131-45.	0.7	17
53	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 1281-1286.	0.9	16
54	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. <i>International Journal of Cancer</i> , 1994, 59, 269-274.	2.3	16

#	ARTICLE	IF	CITATIONS
55	New Target Antigens for Cancer Immunoprevention. <i>Current Cancer Drug Targets</i> , 2005, 5, 221-228.	0.8	16
56	TRAF6 regulates proliferation and differentiation of skeletal myoblasts. <i>Differentiation</i> , 2011, 81, 99-106.	1.0	16
57	Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. <i>Cancer Research</i> , 2022, 82, 708-720.	0.4	16
58	RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. <i>European Journal of Cell Biology</i> , 2008, 87, 163-172.	1.6	15
59	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <i>Cancers</i> , 2019, 11, 1889.	1.7	15
60	Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination. <i>British Journal of Cancer</i> , 1992, 65, 519-522.	2.9	14
61	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	2.1	14
62	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. <i>BMC Cancer</i> , 2014, 14, 137.	1.1	13
63	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by $\beta$ -interferon transfectants through host lymphocytes. <i>International Journal of Cancer</i> , 1995, 61, 425-430.	2.3	12
64	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	0.8	12
65	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1998, 78, 1541-1546.	2.9	11
66	A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome. <i>Human Gene Therapy</i> , 2009, 20, 453-464.	1.4	11
67	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	2.2	11
68	Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. <i>British Journal of Cancer</i> , 1993, 68, 862-867.	2.9	10
69	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 123-128.	1.7	10
70	Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: Lack of autocrine growth modulation. , 1998, 78, 441-445.		10
71	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	1.3	10
72	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Cancer immunoprevention: from mice to early clinical trials. <i>BMC Immunology</i> , 2018, 19, 16.	0.9	9
74	Therapy of murine mammary carcinoma metastasis with interferon $\hat{1}^3$ and MHC gene-transduced tumour cells. <i>British Journal of Cancer</i> , 1996, 74, 1564-1569.	2.9	8
75	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	0.9	8
76	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. <i>British Journal of Cancer</i> , 2012, 107, 1302-1309.	2.9	8
77	APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. <i>European Journal of Cancer</i> , 2009, 45, 2731-2735.	1.3	7
78	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	1.7	7
79	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	1.1	7
80	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. <i>Cell Death and Disease</i> , 2022, 13, 346.	2.7	7
81	INTERLEUKIN 6 GENE-TRANSFECTED MOUSE MAMMARY ADENOCARCINOMA: TUMOUR CELL GROWTH AND METASTATIC POTENTIAL. , 1997, 182, 76-85.		6
82	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. <i>Scientific Reports</i> , 2021, 11, 1563.	1.6	6
83	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. <i>International Journal of Cancer</i> , 2007, 121, 88-94.	2.3	5
84	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. <i>Vaccine</i> , 2011, 29, 4690-4697.	1.7	4
85	Immunoprevention and Immunotherapy of Mammary Carcinoma. <i>Breast Journal</i> , 2010, 16, S39-S41.	0.4	3
86	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2018, 7, e1465164.	2.1	3
87	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. <i>European Journal of Cancer</i> , 2006, 42, 680-687.	1.3	2
88	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. <i>Cells</i> , 2021, 10, 1808.	1.8	2
89	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	1.7	1
90	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937.		1